Thousands of people living with multiple sclerosis in England are set to benefit from a new NHS treatment designed to help them walk more easily and live more independently.
NHS England said fampridine, described as the first medicine designed to improve walking in adults with MS, will now be routinely available on the NHS from 23 July 2026. The move follows a clinical commissioning policy published on 16 July 2026 and is being presented as a step that could make everyday movement easier for eligible patients.
What the new treatment aims to do
MS is a lifelong neurological condition caused by damage to nerves in the brain and spinal cord. Symptoms can include weakness, fatigue, loss of sensation, problems with balance and coordination, and difficulty walking. According to NHS England, fampridine acts like a signal booster for nerves damaged by MS, helping electrical messages travel more effectively to the muscles.
The health service said the treatment could help some patients with routine activities, including moving around the house, getting out independently and spending more time with family and friends. NHS England also said the rollout follows assessment by its Clinical Priorities Advisory Group, which reviews specialist medicines, devices and treatments according to patient benefit and value for money.
Access and wider significance
The announcement is being framed as a shift in access for people with MS in England, with NHS England saying the decision brings availability in line with other UK nations. The policy highlights a focus on both clinical benefit and practical support for people whose mobility is affected by the condition.
For a progressive disease that can affect daily life in many ways, even modest improvements in walking can be meaningful. Fampridine is expected to become part of routine NHS care for eligible adults with MS, giving clinicians another option to support mobility and independence.
The NHS has not described the rollout as a cure, but as a treatment aimed at improving walking ability for adults with MS who meet the relevant criteria. For patients and families, the change represents another sign that specialist therapies are continuing to move into routine use on the NHS.
Source: NHS England announcement
